Search

Your search keyword '"Zahrani MA"' showing total 2 results
Start Over Author "Zahrani MA" Language undetermined
2 results on '"Zahrani MA"'

1. Total body irradiation plus fludarabine compared to busulfan plus fludarabine as 'reduced-toxicity conditioning' for patients with acute myeloid leukemia treated with allogeneic hematopoietic cell transplantation in first complete remission: a study by the Acute Leukemia Working Party of the EBMT

Author

Giebel, S, Labopin, M, Sobczyk-Kruszelnicka, M, Stelljes, M, Byrne, JL, Fegueux, N, Beelen, DW, Rovira, M, Spyridonidis, A, Blaise, D, Bornhauser, M, Karadogan, I, Savani, BN, Nagler, A, Mohty, M, Martin, S, Chevallier, P, Neubauer, A, Damaj, G, Koc, Y, Ganser, A, Collin, M, Yakoub-Agha, I, Ozdogu, H, Araujo, MC, Itala-Remes, M, Orchard, K, Isaksson, C, Bethge, W, Martin, H, Aljurf, M, Faber, E, Caballero, D, Zak, P, Leleu, X, Bay, JO, Rohrlich, PS, Kroger, N, Huynh, A, Schafer-Eckart, K, Milpied, N, Lenhoff, S, Ho, A, Lopez, JLB, Mordini, N, Lioure, B, Halaburda, K, Olivieri, A, Gedde-Dahl, T, Protheroe, R, Tischer, J, Klammer, M, Clausen, J, Potter, V, Ladetto, M, Tilly, H, Deconinck, E, Brecht, A, Muller, LP, Heinicke, T, Carrete, JPT, Bazarbachi, A, Remenyi, P, Rubio, MT, Fanin, R, Perez-Simon, JA, Niels, M, Diez-Martin, JL, Arat, M, Hermine, O, Socie, G, Cornelissen, JJ, Santarone, S, Guyotat, D, Bulabois, CE, Bernasconi, P, Johansson, JE, Vrhovac, R, Greinix, H, Lorenzo, JLL, Apte, S, Craddock, C, Kobbe, G, Zahrani, MA, Dreger, P, Lange, A, Tbakhi, A, Meijer, E, Llamas, CV, Santasusana, JMR, Corradini, P, Benedetti, F, Rambaldi, A, Gandemer, V, Malfuson, JV, Kaare, A, Risitano, A, Petrini, M, Selleri, C, and Wu, DP

Abstract

The optimal conditioning for patients with acute myeloid leukemia in first complete remission treated with allogeneic hematopoietic cell transplantation (allo-HCT) has not been defined so far. In this retrospective study, we compared two "reduced-toxicity" regimens: intravenous busulfan at a total dose of 9.6 mg/kg (3 days) + fludarabine (Bu3/Flu) and total body irradiation at a dose of 8 Gy + fludarabine (TBI8Gy/Flu). In the entire study cohort (n = 518), the probabilities of overall survival (OS), leukemia-free survival (LFS), relapse and non-relapse mortality (NRM) at 2 years for Bu3/Flu and TBI8Gy/Flu were 62% vs. 72.5% (p = 0.051), 59.5% vs. 65% (p = 0.15), 30% vs. 20% (p = 0.01), and 10% vs. 14% (p = 0.18), respectively. In multivariate model for patients

Published
2021

2. COVID-19 and stem cell transplantation; results from an EBMT and GETH multicenter prospective survey

Author

Carlos Vallejo Llamas, Mohsen Al Zahrani, Per Ljungman, Kim Orchard, María J. Jiménez, María Calbacho, Beatriz Aguado, Jose Luis Lopez Lorenzo, Safiye Koçulu Demir, Rafael de la Cámara, Aliénor Xhaard, Rocio Parody Porras, Maria Laura Fox, Rodrigo Martino Bofarull, Daniele Vallisa, José Luis Piñana, Gloria Tridello, Mi Kwon, Angel Cedillo, Anna De Grassi, Nina Knelange, Jane F. Apperley, Malgorzata Mikulska, Jan Styczyński, Stephan Mielke, Nicolaus Kröger, Lucía López-Corral, Fabio Ciceri, Claudia Crippa, Ana Berceanu, National Institute for Health Research (UK), Ljungman, P., de la Camara, R., Mikulska, M., Tridello, G., Aguado, B., Zahrani, M. A., Apperley, J., Berceanu, A., Bofarull, R. M., Calbacho, M., Ciceri, F., Lopez-Corral, L., Crippa, C., Fox, M. L., Grassi, A., Jimenez, M. -J., Demir, S. K., Kwon, M., Llamas, C. V., Lorenzo, J. L. L., Mielke, S., Orchard, K., Porras, R. P., Vallisa, D., Xhaard, A., Knelange, N. S., Cedillo, A., Kroger, N., Pinana, J. L., Styczynski, J., Institut Català de la Salut, [Ljungman P] Department of Cellular Therapy and Allogeneic Stem Cell Transplantation, Karolinska Comprehensive Cancer Center, Karolinska University Hospital Huddinge, Stockholm, Sweden. Division of Hematology, Department of Medicine Huddinge, Karolinska Institutet, Stockholm, Sweden. [de la Camara R] Department of Hematology, Hospital de la Princesa, Madrid, Spain. [Mikulska M] Division of Infectious Diseases, University of Genoa and Ospedale Policlinico San Martino, Genova, Italy. [Tridello G] Pediatric Hematology Oncology, Verona, Italy. [Aguado B] Department of Hematology, Hospital de la Princesa, Madrid, Spain. [Zahrani MA] King Abdul – Aziz Medical City, Riyadh, Saudi Arabia. [Fox ML] Servei d’Hematologia, Vall d’Hebron Hospital Universitari, Barcelona, Spain. Experimental Hematology Group, Vall d’Hebron Institute of Oncology (VHIO), Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus

Subjects
Investigative Techniques::Epidemiologic Methods::Data Collection::Surveys and Questionnaires [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], Male, Cancer Research, medicine.medical_treatment, Hematopoietic stem cell transplantation, Stem cells, virosis::infecciones por virus ARN::infecciones por Nidovirales::infecciones por Coronaviridae::infecciones por Coronavirus [ENFERMEDADES], Medicine, Prospective Studies, Young adult, Prospective cohort study, Child, Immunodeficiency, COVID-19 (Malaltia) - Complicacions, Aged, 80 and over, Hematopoietic Stem Cell Transplantation, Virus Diseases::RNA Virus Infections::Nidovirales Infections::Coronaviridae Infections::Coronavirus Infections [DISEASES], Immunosuppression, Hematology, Middle Aged, Prognosis, Survival Rate, Oncology, Child, Preschool, Hematologic Neoplasms, Infectious diseases, Female, Cèl·lules mare, terapéutica::terapia biológica::tratamientos basados en células y tejidos::trasplante de células::trasplante de células madre::trasplante de células madre hematopoyéticas [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], Haematological diseases, Adult, medicine.medical_specialty, Adolescent, Article, Young Adult, Internal medicine, Mortalitat, Humans, Transplantation, Homologous, Mortality, Survival rate, Aged, Performance status, Cèl·lules mare hematopoètiques - Trasplantació, business.industry, SARS-CoV-2, Infant, COVID-19, técnicas de investigación::métodos epidemiológicos::recopilación de datos::encuestas y cuestionarios [TÉCNICAS Y EQUIPOS ANALÍTICOS, DIAGNÓSTICOS Y TERAPÉUTICOS], medicine.disease, Transplantation, Sang - Malalties, Therapeutics::Biological Therapy::Cell- and Tissue-Based Therapy::Cell Transplantation::Stem Cell Transplantation::Hematopoietic Stem Cell Transplantation [ANALYTICAL, DIAGNOSTIC AND THERAPEUTIC TECHNIQUES, AND EQUIPMENT], business, Follow-Up Studies
Abstract

© The Author(s) 2021., This study reports on 382 COVID-19 patients having undergone allogeneic (n = 236) or autologous (n = 146) hematopoietic cell transplantation (HCT) reported to the European Society for Blood and Marrow Transplantation (EBMT) or to the Spanish Group of Hematopoietic Stem Cell Transplantation (GETH). The median age was 54.1 years (1.0–80.3) for allogeneic, and 60.6 years (7.7–81.6) for autologous HCT patients. The median time from HCT to COVID-19 was 15.8 months (0.2–292.7) in allogeneic and 24.6 months (−0.9 to 350.3) in autologous recipients. 83.5% developed lower respiratory tract disease and 22.5% were admitted to an ICU. Overall survival at 6 weeks from diagnosis was 77.9% and 72.1% in allogeneic and autologous recipients, respectively. Children had a survival of 93.4%. In multivariate analysis, older age (p = 0.02), need for ICU (p < 0.0001) and moderate/high immunodeficiency index (p = 0.04) increased the risk while better performance status (p = 0.001) decreased the risk for mortality. Other factors such as underlying diagnosis, time from HCT, GVHD, or ongoing immunosuppression did not significantly impact overall survival. We conclude that HCT patients are at high risk of developing LRTD, require admission to ICU, and have increased mortality in COVID-19., JA acknowledges the support of the UK NIHR Imperial College Biomedical Research Centre.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results